Clinical Trials Browser

Active not recruiting × abiraterone × Genitourinary × Clear all

NCT04748042 2026-03-06

Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT04647526 2026-01-13

SPLASH

Phase 3 Active not recruiting

455 enrolled 18 charts

Prostatic Neoplasms

NCT04446117 2025-12-18

CONTACT-02

Phase 3 Active not recruiting

575 enrolled 13 charts

Prostatic Neoplasms

NCT03511196 2025-12-04

Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer

Phase EARLY_PHASE1 Active not recruiting

Prostatic Neoplasms

NCT05189457 2025-12-04

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03860987 2025-09-08

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

Phase 2 Active not recruiting

Castrate Sensitive Prostate Cancer

NCT05204927 2025-07-31

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT05288166 2025-06-27

CYCLONE 3

Phase 3 Active not recruiting

925 enrolled 12 charts

Neoplasm Metastasis, Prostatic Neoplasms, Urogenital Neoplasms

NCT04262154 2025-04-27

Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03141671 2024-05-14

Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03934840 2024-02-28

CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT00268476 2023-04-18

STAMPEDE

Phase 2/3 Active not recruiting

11,992 enrolled

Prostatic Neoplasms